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Objectives: Breast cancer mortality is higher among African Americans than for Whites, though their breast 
cancer incidence is lower. This study examines whether this disparity may be due to differential receipt of treat-
ment defined as “standard of care” or “addition to standard of care” by the National Comprehensive Cancer 
Network (NCCN).  
Design: Incident, female breast cancer cases, 2,203 African American and 7,518 White, diagnosed during 
1996-2002 were identified from the Alabama Statewide Cancer Registry. Breast cancer treatment was character-
ized as whether or not a woman received standard of care as defined by the NCCN. For cases characterized as 
receiving standard of care, addition to standard of care was also evaluated, defined as receiving at least one addi-
tional treatment modality according to NCCN guidelines. Logistic models were used to evaluate racial differences 
in standard and addition to standard of care and to adjust for age, stage at diagnosis, year of diagnosis and area of 
residence.  
Results: No racial differences were found for standard (Prevalence Ratio (PR)=1.00) or for addition to standard 
of care (PR=1.00) after adjustment for confounders. When the adjusted models were examined separately by age, 
stage, and area of residence, overall no racial differences were found.  
Conclusion: No racial differences in standard of care and addition to standard of care for breast cancer treat-
ment were found. Therefore, both African Americans and Whites received comparable treatment according to 
NCCN guidelines.  
Key words: Breast Neoplasms, Therapeutics, standard of care, racial disparities, cancer registry 
INTRODUCTION 
Breast cancer is the most common cancer among 
women (about one of every 3 cancers diagnosed) in the 
United States, excluding cancers of the skin [1]. In 2008 
in the United States, 182,460 new female breast cancer 
cases are estimated to occur and 40,480 are expected to 
die from this cause [2]. Even though mortality rates 
have been declining for both races, the decline for Af-
rican Americans is half that of Whites [3]. The breast 
cancer mortality rate is higher among African Ameri-
cans than Whites, though their breast cancer incidence 
rate is lower [3].   
Excessive cancer mortality  in minority popula-
tions, especially African Americans, has long been 
recognized and has been shown to be partly due to 
stage distribution at diagnosis; however, the reasons 
for these racial disparities are not completely under-
stood [1,4]. Several studies have examined whether 
variation in treatment, surgery and/or adjunct therapy 
explains this racial disparity in mortality [5-18, 19].  
Few studies with adequate sample sizes have exam-
ined racial differences between African Americans and 
Whites with regard to receipt of recommended breast 
cancer treatment [10,12,13,16]. Results have been 
mixed with two studies finding a racial difference in Int. J. Med. Sci. 2008, 5 
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treatment [10,16] and two finding no difference after 
adjustment for varying predictors [12,13]. This study 
examines whether part of this racial disparity may be 
due to differences in receipt of National Comprehen-
sive Cancer Network (NCCN) recommended treat-




Data on all first primary incident breast cancer 
cases were identified from the Alabama Statewide 
Cancer Registry (ASCR) founded in 1996. Incident, 
female cases, 2,203 African American and 7,518 White, 
who were 19-65 years of age and living in Alabama 
when diagnosed over the 7-year period 1996-2002, 
were eligible for inclusion in this study. Because stage 
at diagnosis was necessary to assess standard of care 
with the NCCN recommendations (see below: Out-
come Measures), patients with unknown stage were 
excluded from the standard of care assessment as well 
as stage 0 cases so only invasive cancer was examined.  
Outcome Measures 
Standard of care was defined as receiving breast 
cancer treatment as recommended by the NCCN 
guidelines for her specific diagnosis year and stage at 
diagnosis. For example, if the NCCN recommended 
only chemotherapy, the patient received standard of 
care if the patient only received chemotherapy. Among 
those receiving standard of care, addition to standard 
o f c are  w a s defin ed as  re c eip t  o f  t h e NC C N r ec o m -
mended breast cancer treatment plus at least one ad-
ditional treatment modality. Addition to standard of 
care was considered receiving additional treatment 
than recommended. For example, if the NCCN rec-
ommended only chemotherapy and the patient re-
ceived chemotherapy and radiation therapy, the pa-
tient received the additional treatment of radiation 
therapy and would be defined as receiving addition to 
standard of care. Because no treatment for stage IV 
was considered to be appropriate according to the 
NCCN recommendations, all stage IV patients were 
considered to have received standard of care. 
To determine whether or not standard of 
care/addition to standard of care was received, com-
puter algorithms were developed to compare the ac-
tual treatment to recommended treatment for specific 
year of diagnosis and stage according to lymph node 
status, tumor size, age, and estrogen receptor status for 
each breast cancer case. For example, if a breast cancer 
case diagnosed in 1997 with stage II, aged 55 years, 
had a tumor size>50mm, and was ER+, the treatment 
this patient should have received included mastec-
tomy or lumpectomy, radiation therapy, and hormone 
therapy according to NCCN recommendations. If the 
patient received all of these treatments, the patient 
received standard of care. If the patient also received 
chemotherapy which was not recommended, then the 
patient received addition to standard care. The prin-
cipal investigator and two assistants composed and 
checked the algorithms as a means of quality control.  
NCCN recommendations were revised in 1996, 
1997, 1999 and 2000 though changes were minimal. 
NCCN does not allow publication of detailed guide-
lines from previous years, however a summary of the 
recommendations are as follows: In most years, mas-
tectomy without radiation or lumpectomy with radia-
tion was recommended for stages I and II. Radiation 
with mastectomy was typically recommended only for 
cases having large tumors. Chemotherapy was typi-
cally recommended for women younger than 50 years 
old or those in stage III, and hormone therapy was 
recommended for women whose estrogen receptor 
status was positive and whose age was 50 years or 
older.  
Study Measures 
Information collected from ASCR included iden-
tification of the incident breast cancer cases, demo-
graphics, estrogen receptor status, stage at diagnosis, 
year of diagnosis, lymph node status, tumor size, type 
of breast cancer treatment received (surgery, radiation, 
chemotherapy, and hormone therapy), and county of 
residence. The NCCN guidelines are based on clinical 
staging, thus the American Joint Committee on Cancer 
(AJCC) clinical staging was used when available. 
When  clinical stage was missing (38% of cases), the 
AJCC pathological stage was used allowing the per-
c e n t  o f  m i s s i n g  t o  b e  o n l y  1 7 . 7 %  o f  c a s e s  ( N = 1 7 2 1 ) .  
Using the United States Census definitions, Metro-
politan Statistical Area (MSA) counties were consid-
ered urban areas while non-MSA counties were con-
sidered rural areas.  
Statistics 
Chi-square tests were used to evaluate differ-
ences in characteristics between African Americans 
and Whites. A binary logit model was used to evaluate 
the relationship of standard of care and race (African 
American versus White), computing the crude and 
adjusted prevalence ratios (PRs) and the correspond-
ing 95% confidence intervals [20]. PRs were adjusted 
for age, stage of diagnosis, year of diagnosis, and area 
of residence (urban vs. rural). Because estrogen recep-
tor status was highly correlated to hormone therapy, 
estrogen receptor status was not included in the mul-
tivariate models. Separate models were computed by 
area of residence, stage at diagnosis, and age.  Int. J. Med. Sci. 2008, 5 
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P-values < 0.05 were considered to be statistically 
significant. Analyses were performed using SAS sta-
tistical software version 9.0 (SAS, Cary, NC). 
RESULTS 
Characteristics of incident African American and 
White female breast cancer cases from 1996-2002 are 
shown in Table 1. African Americans were younger at 
the time of diagnosis, more likely to be estrogen re-
ceptor negative and more likely to be diagnosed at a 
later stage compared to Whites (all p values <0.001). 
African Americans were more likely to undergo mas-
tectomy and chemotherapy compared to Whites (both 
p<0.001), while Whites were more likely to undergo 
lumpectomy (p<0.001) and radiation (p=0.06). When 
each breast cancer treatment (surgery, radiation, che-
motherapy and hormone therapy among estrogen re-
ceptor positive) was evaluated in a binary logistic 
model, no racial differences were found when adjusted 
for age at diagnosis, stage at diagnosis, year of diag-
nosis and area of residence (data not shown). 
Table 1. Characteristics of incident breast cancer cases in Alabama, 1996-2002 
All   White   African-American      
N*=9721 N*=7518 N*=2203   
    N   (%)   N   (%)   N   (%)  p-value 
Age (years)           
 19-39  1044  (10.8)  678  (9.0)  366  (16.6)  <0.001 
  40-49  2742  (28.2)  2006  (26.7) 736 (33.4)   
  50-59  3715  (38.2)  2969  (39.5) 746 (33.9)   
  60-65  2220  (22.8)  1865  (24.8) 355 (16.1)   
Estrogen Receptor         
  Positive  4205  (43.2)  3423  (45.5) 782 (35.5)  <0.001 
  Negative  2039  (21.0)  1433  (19.1) 606 (27.5)   
 Other & Unknown  3477  (35.8)  2662  (35.4)  815  (37.0)   
Stage         
  0/I  3646  (37.5)  3054  (40.6) 592 (26.9)  <0.001 
  II  3304  (34.0)  2406  (32.0) 898 (40.8)   
  III  690 (7.1) 462 (6.1) 228  (10.3)   
  IV  360 (3.7) 246 (3.3) 114 (5.2)   
  Unknown  1721  (17.7)  1350  (18.0) 371 (16.8)   
Year of Diagnosis         
  1996-1999  5608 (57.9) 4313 (57.5) 1295 (59.0) 0.23 
  2000-2002  4081  (42.1)  3181  (42.5) 900 (41.0)   
Surgery          
  Mastectomy  5137 (52.8) 3924 (52.2) 1213 (55.1)  <0.001 
  Lumpectomy  3492  (35.9)  2786  (37.1) 706 (32.0)   
  None  656 (6.8) 472 (6.2) 184 (8.4)   
  Unknown  436 (4.5) 336 (4.5) 100 (4.5)   
Chemotherapy         
  Yes  4738 (48.7) 3485 (46.4) 1253 (56.9)  <0.001 
  No  4651  (47.8)  3782  (50.3) 869 (39.5)   
  Unknown  332 (3.5) 251 (3.3)  81  (3.6)   
Radiation Therapy         
  Yes  3043  (31.3)  2399  (31.9) 644 (29.2) 0.06 
  No  6595 (67.8) 5055 (67.2) 1540 (69.9)   
  Unknown  83 (0.9) 64 (0.9) 19 (0.9)   
Estrogen Receptor POSITIVE         
 Hormone  therapy         
  Yes  1518  (36.1)  1265  (37.0) 253 (32.4) 0.02 
  No  2480  (59.0)  2000  (58.4) 480 (61.4)   
  Unknown  207 (4.9) 158 (4.6)  49  (6.2)   
Estrogen Receptor NEGATIVE         
 Hormone  therapy         
  Yes  162 (8.0) 124 (8.7)  38  (6.3)  0.15 
 No  1852  (90.8)  1290  (90.0)  562  (92.7)   
  Unknown  25 (1.2) 19 (1.3)  6  (1.0)   
Urban         
 Yes  6756  (69.5)  5131  (68.3)  1625  (73.8)  <0.001 
 No  2869  (29.5)  2302  (30.6)  567  (25.7)   
  Unknown  96 (1.0) 85 (1.1) 11  (0.5)  
*: Due to missing data, total N for each variable may not equal total N for group.
  Int. J. Med. Sci. 2008, 5 
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  Frequencies and percentages of women who re-
ceived standard of care and addition to standard of 
care are presented in Table 2. Only two-thirds of all 
breast cancer cases received standard of care. No dif-
ferences were found between African Americans and 
Whites in receipt of standard of care or addition to 
standard of care (Table 3). Stage at diagnosis and area 
of residence were statistically significant in both the 
standard of care and addition to standard of care ad-
justed models while year of diagnosis was significant 
only in the standard of care model. Compared to 
women who had stage I, women with stage II were 
18% less likely to receive standard of care (Adjusted 
PR: 0.82 (0.78, 0.87)) and women who had stage III 
were 23% more likely to receive standard of care (Ad-
justed PR: 1.23 (1.16, 1.29)). Compared to those with 
stage I, women with stage II were 23% less likely to 
receive addition to standard of care (Adjusted PR: 0.77 
(0.68, 0.87)) and those with stage III (Adjusted PR: 1.20 
(1.06, 1.35)) or stage IV (Adjusted PR: 2.29 (2.11, 2.47)) 
w e r e  m o r e  l i k e l y  t o  r e c e i v e  a d d i t i o n  t o  s t a n d a r d  o f  
care. Those living in urban areas were 7% more likely 
to receive standard of care compared to those living in 
rural areas (Adjusted PR: 1.07 (1.01, 1.12)). Women 
diagnosed during 2000-2002 were 6% less likely to 
receive standard of care compared to women diag-
nosed during 1996-1999 (Adjusted PR: 0.94 (0.90, 
0.99)). For receipt of addition to standard of care, area 
of residence was significant with those in urban areas 
being 8% more likely to receive addition to standard of 
care compared to those in rural areas (Adjusted PR: 
1.08 (1.01, 1.16)).  
   Table 4 presents similar findings separately for 
African Americans and Whites. For both races, women 
with stage II were less likely to receive standard of care 
and addition to standard of care compared to women 
with stage I, and women with stage III or IV were more 
likely to receive addition to standard of care compared 
to women with stage I. When separate binary logit 
models were used for area of residence, stage, and age, 
no significant differences were found (data not 
shown). 
 
Table 2. Distribution of women who received standard of care and addition to standard of care for their breast cancer treatment 
according to selected characteristics. 
  Received Standard of Care 
(Yes: N=2781) 
  Received Addition to Standard of Care 
(Yes: N=1370)   
   N     Yes (%)  p-value*      N     Yes (%)  p-value*  
Race               
 White  2141    (62.6) 0.31  1035    (42.7) 0.51 
 African American  640    (64.3)    335    (44.0)   
Age (years)                 
 19-39  336    (67.3) 0.13  138    (32.2) 0.05 
 40-49  807    (63.5)    394    (42.8)   
 50-59  1025    (61.7)    535    (45.4)   
 60-65  613    (62.2)    303    (42.4)   
Estrogen Receptor               
 Positive  1501    (56.3) <0.001  803    (48.6) <0.001 
 Negative  887    (74.5)    285    (29.2)   
 Other  393    (70.3)    282    (50.6)   
Stage†               
 0/I  1300    (65.6) <0.001  520    (39.0) <0.001 
 II  968    (54.0)    293    (29.9)   
 III  513    (80.0)    241    (47.0)   
 IV  n/a    n/a    316     (87.8)   
Year of Diagnosis               
 1996-1999  1262    (61.7) 0.10  754    (42.7) 0.74 
 2000-2002  1519    (64.1)    615    (43.3)   
Urban               
 Yes  2031    (63.8) 0.003  768    (37.3) 0.71 
 No  712    (60.0)    272    (37.1)   
*: Percent “yes” in each level of specific category. †: Stage IV could not be included in standard of care because all cases with stage IV were 
considered to be standard of care in computer algorithm.  Int. J. Med. Sci. 2008, 5 
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Table 3. Prevalence ratios for standard of care and addition to standard of care for breast cancer treatment. 
   Standard of Care 
(N=4375) 
  Addition to Standard of Care 
(N=3146)  
Variable Crude  PR *     Adjusted PR (95 % CI) †   Crude  PR *     Adjusted PR (95 % CI) † 
Race            
 White  1.00    1.00    1.00    1.00 
 African American  1.03    1.00 (0.95, 1.05)    1.03    1.00 (0.93, 1.07) 
Age group            
 19-39  1.00    1.00    1.00    1.00 
 40-49  0.94    0.97 (0.91, 1.04)    1.15    1.06 (0.92, 1.21) 
 50-59  0.92    0.94 (0.88, 1.01)    1.22    1.02 (0.89, 1.17) 
 60-65  0.92    0.95 (0.88, 1.02)    1.14    1.04 (0.90, 1.19) 
Stage            
 I  1.00    1.00    1.00    1.00 
 II  0.82    0.82 (0.78, 0.87)    0.77    0.77 (0.68, 0.87) 
 III  1.22    1.23 (1.16, 1.29)    1.20    1.20 (1.06, 1.35) 
  IV n/a    n/a    2.25    2.29 (2.11, 2,47) 
Year of diagnosis            
 1996-1999  1.00    1.00    1.00    1.00 
 2000-2002  0.96    0.94 (0.90, 0.99)    1.01    0.98 (0.92, 1.04) 
Urban            
 No  1.00    1.00    1.00    1.00 
 Yes  1.06    1.07 (1.01, 1.12)    0.99    1.08 (1.01, 1.16) 
*: PR=Prevalence ratios 
†: Prevalence ratios were adjusted for all variables in the table. 
Table 4. Race specific prevalence ratios
* for standard of care and addition to standard of care. 









Age group         
 19-39  1.00    1.00 1.00  1.00 
 40-49  1.00 (0.92, 1.08)    0.99 (0.88, 1.11)  1.08 (0.91, 1.28)  1.04 (0.87, 1.25) 
 50-59  0.96 (0.89, 1.04)    0.97 (0.86, 1.09)  1.06 (0.90, 1.25)  1.03 (0.85, 1.24) 
 60-65  0.96 (0.88, 1.05)    0.96 (0.85, 1.09)  1.05 (0.88, 1.26)  1.04 (0.84, 1.27) 
Stage         
 I  1.00    1.00 1.00  1.00 
 II  0.80 (0.75, 0.85)    0.92 (0.82, 1.04)  0.77 (0.68, 0.88)  0.92 (0.78, 1.08) 
 III  1.24 (1.17, 1.31)    1.24 (1.11, 1.39)  1.24 (1.09, 1.41)  1.06 (0.90, 1.26) 
 IV  n/a    n/a  2.20 (2.02, 2.40)  1.73 (1.50, 2.00) 
Year of diagnosis         
 1996-1999  1.00    1.00 1.00  1.00 
 2000-2002  0.97 (0.92, 1.02)    0.87 (0.79, 0.96)  0.98 (0.90, 1.05)  0.99 (0.88, 1.11) 
Urban         
 No  1.00    1.00 1.00  1.00 
 Yes  1.07 (1.01, 1.13)    1.05 (0.94, 1.18)  1.09 (1.01, 1.19)  1.00 (0.88, 1.13) 
*: Prevalence ratios were adjusted for all variables in the table. 
†: AA=African American 
 
DISCUSSION 
Breast cancer mortality is higher among African 
Americans than for Whites; though their breast cancer 
incidence is lower [3]. This study examines whether or 
not this racial disparity was due to differences in the 
receipt of NCCN recommended breast cancer treat-
ment. No racial differences were found for standard of 
care or addition to standard of care overall or by age, 
stage, and area of residence. African Americans and 
Whites received comparable recommended treatment 
even though there were racial differences by type of 
treatment received. Therefore, the higher mortality 
rate of African Americans compared to Whites was 
shown not to be due to treatment practices varying 
from the NCCN recommendations. However, the 
current study found that only two-thirds of women in 
the overall study population received standard of care 
for their breast cancer. While no racial differences were 
found, many breast cancer cases are not receiving 
standard of care according to the NCCN guidelines. 
This could be due to patients’ preferences, which could 
not be evaluated by the current study. Int. J. Med. Sci. 2008, 5 
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Most previous studies have examined only the 
frequencies of types of breast cancer treatment (sur-
gery, radiation, chemotherapy, hormone therapy) re-
ceived. Muss et al [12]  reported that fewer African 
Americans with stage II node-positive disease had 
breast-conserving surgery, but race was no longer a 
significant factor in surgery or systemic therapy after 
adjustment for tumor size, co-morbidity, age, and es-
trogen receptor status. Another study with 65 African 
American and 186 White cases examined breast cancer 
treatment among rural women in North Carolina and 
found no difference in surgery and adjunct therapy 
between African Americans and Whites [13]. The cur-
rent study examined the frequencies of types of breast 
cancer treatment, but also evaluated the receipt of 
recommended care for each woman depending on her 
stage at diagnosis, lymph node status, tumor size, age, 
and estrogen receptor status. The current study had a 
large number and large proportion of African Ameri-
can cases and found no racial differences in standard 
and addition to standard of care.  
The differences in receipt of chemotherapy have 
also been examined as a possible explanation for racial 
disparities in breast cancer mortality. Muss et al [12] 
found that no statistically racial differences in receipt 
of chemotherapy in the multivariate analysis [OR=0.70 
(0.40, 1.20)]. Similarly, the study by Tropman et al [13] 
found no racial differences in receipt of adjuvant 
therapy for breast cancer. However, these studies did 
not examine whether or not chemotherapy was ap-
propriate and/or recommended. 
Two previous studies  [10,16] examined racial 
differences related to recommended breast cancer 
treatment. In 1999 Breen et al [16] defined minimum 
expected therapy according to NIH Consensus con-
ference proceedings and reported that 16% Whites 
received minimum expected therapy for their stage of 
breast cancer compared to only 21% African Ameri-
cans. Similarly, another study had an expert 
NCI-appointed committee to define patterns of care 
and found that African Americans were as much as 6 
percentage points less likely to have had treatment 
with radiation after mastectomy [10]. While both of 
these findings were statistically significant, a 5-6% 
difference is not clinically relevant. Both of these pre-
vious studies based their definition of recommended 
care on stage only. Confirming these previous findings 
in recommended care, the current study found no ra-
cial differences in standard and addition to standard of 
care, taking into account not only stage but also lymph 
node status, tumor size, age, and estrogen receptor 
status as considered by the NCCN when making its 
recommendations. 
Also consistent with previous research, the cur-
rent study found that African Americans were 
younger at diagnosis, less likely to be estrogen recep-
tor positive, and had a later stage at diagnosis com-
pared to Whites (Table 1). Also, women in urban areas 
were slightly more likely to receive standard and ad-
dition to standard of care than women in rural areas 
(Table 2). This finding probably reflects better access to 
care for women in urban areas as most cancer treat-
ment facilities are located there. 
One important and surprising finding was 
among women with stage II, representing one third of 
the study population. Women with stage II were less 
likely to receive standard and addition to standard of 
care compared to women with stage I; while women 
with stage III were more likely to receive standard and 
addition to standard of care compared to women in 
stage I. This finding was consistent in the overall ad-
justed models for standard and addition to standard of 
care as well as the adjusted models by race. The un-
usual finding for women with stage II not receiving 
standard of care is primarily due to not receiving ra-
diation therapy when recommended compared to 
those in stage I (data not shown). This finding was true 
in all but one subcategory of women, those with tu-
mors > 50mm. For women with large tumors and stage 
II disease, Whites with mastectomy were less likely to 
receive radiation than African Americans (32.3% vs. 
42.9%, respectively). Radiation therapy is primarily for 
local recurrence of breast cancer and would not be 
expected to affect survival. 
One limitation of the current study is that the 
ASCR does not have complete information on breast 
cancer cases that are treated in another state. Another 
limitation is that the ASCR does not collect informa-
tion on co-morbidity, which may affect choice of breast 
cancer treatment. The analyses were restricted to 
women treated in Alabama and were under the age of 
65 years when diagnosed, so the affect of incomplete 
treatment information and co-morbidity was reduced. 
Also, patient compliance to treatment and socioeco-
nomic status were not assessed because this informa-
tion was not available from the ASCR. Another limita-
tion was that 17.7% of cases (N=1721) were missing 
information on stage at diagnosis. Without the stage at 
diagnosis, the standard of breast cancer treatment 
could not be determined. However, those with un-
known stage tended to be only slightly less likely to 
have surgery, chemotherapy, radiation, and hormone 
therapy compared to those with known stage. The 
current study was also limited in that available insur-
ance data was recorded as the primary payer for 
treatment. Because hierarchy of how insurance data is Int. J. Med. Sci. 2008, 5 
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classified was unknown, insurance could not be used 
in our analysis.  
Completeness of surgery, chemotherapy and ra-
diation data for the ASCR has been examined in a 
study undertaken by the authors which showed that 
chemotherapy is accurately reported but there is an 
underestimation of surgery and radiation [21]. How-
ever, the differences were not due to patient charac-
teristics. The completeness of treatment data was not 
based on race, appeared to occur at random, and 
should only minimally affect the results of the current 
study. Finally, while NCCN guidelines do not substi-
tute for careful physician evaluation and comprehen-
sive care of patients, the current study does allow ob-
jective study of the standard of care in a large popula-
tion of breast cancer patients. 
A strength is that our study found that African 
Americans were younger at time of diagnosis of their 
breast cancer and were diagnosed at a later stage, 
which is consistent with other studies. The current 
study has a large proportion of African Americans 
(23%). Further, not only did we examine standard of 
breast cancer treatment but also the addition to stan-
dard of care. The current study used many criteria to 
classify standard of care compared to previous studies 
that did not include all relevant information for de-
termination of meeting the standard and to date, no 
other study has examined the racial differences in ad-
dition to standard of breast cancer treatment.    
Another reason proposed to explain why African 
Americans have a higher death rate from their breast 
cancer is advanced stage of disease at the time of di-
agnosis. Several previous studies have suggested that 
the racial disparity in mortality can be explained by 
African American women being diagnosed at more 
advanced stages [22,23]. The current study found that 
African American cases were indeed diagnosed at later 
stages than White cases. We also found among those in 
stage III, African Americans were more likely to have 
received standard of care and addition to standard of 
care compared to Whites. Therefore, meeting or ex-
ceeding standard of care of breast cancer treatment 
does not explain this disparity. In fact, it may be low 
adherence to the treatment regimen which is limiting 
survival of African American patients, but this ques-
tion was out of the scope of our large population-based 
study, as this data is not provided by the cancer regis-
try. 
In conclusion, we found little in the way of racial 
differences in standard and addition to standard of 
care for recommended breast cancer treatment in a 
large population with a high proportion of African 
Americans. Therefore, other reasons explain the racial 
disparity in breast cancer treatment mortality. Future 
studies could examine patient compliance to treatment 
and time from diagnosis to treatment as possible ex-
planations for the racial disparity in mortality. A sec-
ond major finding was that only two-thirds of our 
study population was found to have received standard 
of care. Differences were found in standard of care and 
addition to standard of care according to stage at di-
agnosis and area of residence which bears further ex-
ploration.  
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